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Out-of-Hospital Cardiac Arrest
Should We Rely on Biomarkers?*Luigi M. Biasucci, MD, Giovanna Liuzzo, MD, PHD“Lasciate ogni speranza di riveder lo
cielo o voi che entrate.”
—Dante Alighieri’s Divina Commedia (1)SEE PAGE 2104T hese words, on the entrance of the “Inferno”in the Divina Commedia, translate as“Abandon all hope you who enter here.”
Fortunately, these words are inappropriate in con-
temporary medicine: mortality is getting lower in all
areas, and even those who experience a resuscitated,
out-of-hospital cardiac arrest (OHCA) have good
“hopes” of leaving the hospital alive, with few or no
neurological reliquats (2). However, in many life-
threatening conditions, including OHCA, physicians
still lack information on the likelihood of a patient’s
recovery. The experience of an OHCA is dramatic for
patients’ relatives and often frustrating for doctors.
Both may feel helpless, as the risk of death and no
cerebral recovery is still high. A recent collaborative
study in Northern Europe (3) found a survival rate
in OHCA around 50%. Although the good news
was that only 10% of those who survived had severe
neurological impairment, this study further raises
interest in any tool that might improve prognosis
or prognostication of recovery. Prognostication on
the fate of these patients is, indeed, difﬁcult, and
our ability to predict their outcomes often includes
guesswork. In the past, the majority of studies*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.used the Glasgow Outcome Scale and the Cerebral
Performance Category to assess prognosis after
OHCA; both methods are based on neurological exam-
inations and, therefore, are intrinsically limited by
the post-cardiac arrest conditions, including seda-
tion (3). Conversely, management of OHCA patients
would require effective prognostic methods to cor-
rectly allocate resources and reduce some stress for
the patient’s relatives. This issue obviously raises
important ethical considerations.In this issue of the Journal, Stammet et al. (4)
report on the possibility that neuron-speciﬁc en-
olase (NSE) might improve prognostication in OHCA
in addition to the current clinical and biological
indexes. NSE is a dimeric intracellular glycolytic
enzyme comprised of 2 subunits, gg or ag, present
in neurons and in other cells of neuroectodermal
origin, but they also are found in erythrocytes (5) and
platelets (6). Serum NSE has been widely used in
OHCA and is the only biochemical marker of brain
injury accepted for neurological prognostication after
cardiac arrest (7,8). Recent studies on hypothermia
after cardiac arrest, however, gave conﬂicting results,
questioning the relevance of recommended cut-off
values and reducing the interest in this biomarker
(9,10). Methodological issues surfaced, questioning
the robustness of the analysis in conditions such
as hemolysis (11,12), whereas the small number of
patients enrolled in previous studies might explain,
under a statistical point of view, the variability of
the results (7).
What does the study by Stammet et al. (4) add to
all this? Taking advantage of the robustness of the
TTM (Target Temperature Management After Cardiac
Arrest) trial (13), which demonstrated the lack of
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OHCA, they had the possibility to approach the issue
of NSE as a prognosticator of survival in these pa-
tients. TTM, a multicenter, randomized trial, enrolled
939 patients, of whom 686 had complete data and
blood samples at 3 different times (24, 48, and 72 h
after return of circulation). Neurological prognosti-
cation and withdrawal of life-supporting therapies
were standardized according to the TTM trial proto-
col. The primary outcome of the study was neuro-
logical function at 6 months, dichotomized to good
or poor outcome according to the Cerebral Per-
formance Category scale. Secondary outcomes were
good or poor, according to the modiﬁed Rankin scale
at 6 months and all-cause mortality at the end of
the trial. NSE was found to be a robust predictor of
outcome. There was no signiﬁcant difference be-
tween temperature groups at any time point for any
of the study’s outcomes.
As a major strength, this investigation was a pre-
deﬁned substudy investigating a serum biomarker
for prognostication after OHCA within the largest,
multicenter, randomized clinical trial studying 2
target temperature regimens in comatose cardiac ar-
rest patients. It represents the largest prospective
study of its kind. Other studies reporting lower NSE
values in 33C-treated patients had limitations,
notably due to the comparison of patients treated at
33C to historical control subjects (14) or to a small
sample size (15). The results of NSE values were not
available to the treating physicians during the trial
and, therefore, did not inﬂuence prognostication of
patients. A unique feature of the TTM trial is that
prognostication and withdrawal were standardized,
which increases the validity of the results on NSE
of the current study (13).
Moreover, the study methodology is strong and
convincing. All analyses were performed in a single
core laboratory limiting the inﬂuence of assay vari-
ability and laboratory processing; samples with
hemolysis were eliminated from the study. The sta-
tistical analysis was reliable. NSE levels at 24, 48, and
72 h were added to a clinical multivariable logistic
model containing temperature allocation, age, sex,
bystander cardiopulmonary resuscitation, ﬁrst moni-
tored rhythm, time from cardiac arrest to return
of spontaneous circulation, lactate levels, and circu-
latory shock on admission.
Thus, the study convincingly demonstrates that
adding NSE to the other clinical parameters signiﬁ-
cantly improves the ability to predict a poor neuro-
logical outcome. High NSE cut-off values (with #5%
false positive rates and tight 95% conﬁdence in-
tervals) at 48 and 72 h offer reliable prediction of pooroutcomes with sufﬁcient sensitivity to remain clini-
cally useful within a multimodal prognostication
package, including clinical examination, imaging,
neurophysiology, and biomarkers.
However, the authors themselves point out some
limitations of their study. Although a pre-deﬁned
substudy of the TTM trial, not all sites enrolling in
the main trial participated in biomarker sampling. Not
all patients had blood samples taken at every time
point, and there was no external quality control at
each participating site where samples were collected
and pre-analytically processed.
Second, although biomarkers are unaltered by
sedation and may, therefore, be a more objective
marker of brain injury, they have a general limitation
that their measurement is punctual, whereas pro-
duction or secretion is a dynamic process, high-
lighting the importance of serial measurements to
best predict outcome. Furthermore, brain biomarkers
measured in circulating blood might have some
additional weaknesses, as the integrity of the blood-
brain barrier after ischemia-reperfusion injury in
individuals cannot be measured and may vary sub-
stantially. In the case of NSE, which is predominantly
released from neural and neuroendocrine cells,
caution is warranted as serum levels might reﬂect
variable degrees of brain damage.
A further limitation may be the scarcity of cardio-
logical data that might affect recovery, such as blood
pressure or left ventricular ejection fraction. Never-
theless, these data will provide a milestone for the
next years in studies on OHCA and a reference for
clinicians dealing with this issue.
These study results also indicate additional con-
siderations. The evidence of a signiﬁcantly better
neurological outcome in OHCA for those who were
resuscitated by a bystander suggests that efforts to
improve the knowledge of basic life support in the
general population and the availability of automatic
deﬁbrillators in the proper locations are integral.
Also, the availability of different assays for NSE hav-
ing different cut-off values may indeed represent a
limitation for the widespread clinical use of this
biomarker. Even if each assay has reliable analytical
properties, comparisons are difﬁcult, and the vari-
ability of the data generates confusion and frustra-
tion, with impossibility to apply a single decision
limit to all subjects. This is similar to what is
happening for troponins in cardiology, with contin-
uous redeﬁnition of the proper decision limits (16),
and the restless search for novel biomarkers (17).
However, biomarkers, often seen as the “holy grail”
of medicine, must be accepted for what they are and
what they can give. Few of them are near-perfect
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healthy from the unhealthy, and in many cases (as in
the case of high-sensitivity troponin), biomarkers
require a high level of clinical judgment from the
physicians (18) for their correct utilization.
In terms of ethical, clinical questions, such as
making the decision for a patient with irreversible
brain death or poor neurological recovery, uncertain
biomarker data should not be taken into consider-
ation. The authors correctly propose that life support
should not be ended on the basis of a biomarker
level. Therefore, they recommend using NSE in a
dynamic approach with serial measurements within
a comprehensive prognostication protocol that in-
cludes clinical examination, electroencephalogram,
brain imaging, and somatosensory (19). Once ir-
reversible brain damage is diagnosed, it opensimportant bioethical issues on the continuation of
care and life support. For these reasons, the need for
correct prognostication in OHCA in particular, but in
all ﬁelds of medicine, is important. Because we want
to save the lives of our patients, provide trusted in-
formation to their relatives, and correctly allocate
resources, we need a robust evidence, unfaultable
methodologies, and infallible biomarkers. Therefore,
studies, such as this one by Stammet et al. (4), that
can improve our ability to deﬁne a correct diagnosis
are welcome.
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